Long-term toxicity after cancer treatment has gained increasing clinical attention. We evaluated pulmonary function in long-term survivors of testicular cancer (TC).
INTRODUCTION
Today, germ cell testicular cancer (TC) has a favorable prognosis because of the introduction of cisplatin-based chemotherapy in the late 1970s, a multimodal treatment approach, disease monitoring by tumor markers, and more reliable radiologic staging. 1 The overall cure rate exceeds 95%, and approximately 80% of patients with advanced disease achieve a durable remission.
2 TC is the most common malignancy in men aged 15 to 44 years, 2 and these young men have a near-normal life expectancy after being successfully treated. Thus, evaluation of long-term complications is increasingly important.
Previous studies concerning pulmonary toxicity in TC patients have focused on the toxic effects of bleomycin during or after treatment. Bleomycin was introduced in the treatment of disseminated TC in the early 1970s, and pulmonary toxicity was the major dose-limiting adverse effect. 3 Bleomycin may cause pneumonitis, which may occasionally progress to pulmonary fibrosis during or shortly after treatment. [4] [5] [6] [7] The majority of prior studies on pulmonary function during or after treatment for TC focused on chemotherapy-treated patients only, included a small number of individuals, and/or had a short follow-up period. [8] [9] [10] [11] [12] [13] [14] [15] [16] In these studies, spirometric changes observed during treatment were all normalized at follow-up.
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
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One patient had follow-up time Ͻ 5 years (ie, 4.3 years). †No. of cigarette packs per day multiplied by number of smoking years. ‡Pack year of 0 indicates never smoker.
The aim of this study was to evaluate pulmonary function according to treatment (surgery, radiotherapy, and chemotherapy) in a large, unselected group of long-term TC survivors.
PATIENTS AND METHODS

Study Patients
All Norwegian long-term survivors (Ն 5 years) of unilateral germ cell TC who were aged 18 to 75 years and who were treated during 1980 to 1994 were invited to participate in a national, multicenter, follow-up survey at five university hospitals. The follow-up was carried out during 1998 to 2002 and consisted of a 219-item, mailed questionnaire and an outpatient clinical examination that included spirometry. 
Treatment
On the basis of previously described treatment principles, 21,23 the TC survivors were categorized into five treatment groups according to initial and eventual relapse treatment: surgery only, including orchiectomy and possibly retroperitoneal lymph node dissection (RPLND); radiotherapy (RT) only; chemotherapy with a cumulative dose of cisplatin Յ 850 mg (lower-dose group); chemotherapy with a cumulative dose of cisplatin greater than 850 mg (higher-dose group); or cisplatin-based chemotherapy (any dose) and pulmonary surgery (cis/pulmsurg).
The cutoff point for the two chemotherapy groups was set at cisplatin 850 mg to roughly differentiate between patients who received standard four courses or fewer and those who received more than four courses or higherdose chemotherapy regimens as a result of poor prognosis, inadequate response, progression, or relapse. 23 Most chemotherapy-treated patients (n ϭ 375 [94%] of 398) received cisplatin-based chemotherapy, primarily in combination with etoposide and bleomycin (BEP) or vinblastine and bleomycin (CVB). Twenty-three patients (6%) who received carboplatin instead of cisplatin according to research protocols 24, 25 were included in the lowerdose group.
Assessments
The spirometries were carried out with Welch Allyn Pneumocheck 61000 (Welch Allyn Inc, Skaneateles, NY) at NRH, Vitalograph (Vitalograph Inc, Lenexa, KS) at Haukeland, and Sensormedics VMAX227 (Cardinal Health Inc, Dublin, OH) at UNN. Spirometry variables included forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1). The largest FVC and FEV1 from at least three maneuvers were reported for patients at Haukeland and UNN, in accordance with recommendations for spirometry maneuvers.
26 For patients at NRH, one successful maneuver was performed and was reported accordingly. The spirometry variables were expressed in absolute values and in percentages of predicted normal values (FVC%pred and FEV1%pred respectively, of FVC and FEV1). Predicted normal values were calculated on the basis of internationally approved equations. 27 Restrictive lung disease was defined as FEV1/FVC Ն 70% and FVC%pred less than 80%. 18, 28 Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters (kg/m 2 ). Nonfasting blood samples were drawn at each hospital laboratory primarily between 8:00 AM and 12:00 PM. Levels of serum total testosterone were determined by using a commercial immunoassay, and similar reference ranges were used at each hospital.
Information regarding self-reported dyspnea, pulmonary disease, use of asthma medication, smoking habits, and physical activity were obtained from the questionnaire. Respondents with missing data on pulmonary disease or use of asthma medication were classified without such disease or medication, respectively. Participants who reported having asthma and/or regular use of asthma medication were classified as having asthma. Dyspnea was assessed by the following question: "To what degree have you suffered from dyspnea during the last 12 months?" The response alternatives were much, some, or not at all. All patients who reported some or much were classified as having dyspnea.
Physical activity was assessed by two questionnaire items, which assessed activity at a low physical activity level (eg, walking) and a high level (ie, exercises leading to sweating and breathlessness). On the basis of the responses, physical activity was divided into three categories: none, moderate, or high. 29 Cigarette smoking was assessed by pack years, as described in a previous publication.
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Statistical Analysis
Mean doses of cytotoxic drugs in the two chemotherapy groups were compared by using the t test. FVC, FEV1, FVC%pred, and FEV1%pred were considered normally distributed. Continuous variables were analyzed by using multiple linear regression, whereas dichotomous variables were analyzed by using multiple logistic regression. The surgery group was used as reference to compare the different treatment groups.
All regression analyses were adjusted for age. Analyses of FVC, FVC%pred, FEV1, and FEV1%pred were additionally adjusted for total testosterone, BMI, pack years, and physical activity. To evaluate the impact of smoking on pulmonary function, spirometry variables were additionally analyzed to compare ever-versus never-smokers.
For chemotherapy-treated patients, age at diagnosis (Ͼ 40 years v Յ 40 years [reference]) and major abdominal surgery (ie, RPLND; yes v no [reference]) were evaluated as possible predictors for restrictive lung disease.
Because one of the three involved centers deviated from the standardized maneuver of spirometry, 26 we evaluated if there was any interaction between institution and treatment group (categoric variables). The multiple regression analyses revealed no significant interactions for the different dependent variables (FVC: P ϭ .14; FVC%pred: P ϭ .12; FEV1: P ϭ .48; FEV1%pred: P ϭ .46; restrictive lung disease: P ϭ .88). The treatment institution also was evaluated as a possible confounding factor. None of the estimates changed significantly when the treatment institution was included in the analyses.
The regression coefficient ␤ indicated the mean difference (in liters [FVC] or liters per second [FEV1]) compared with the reference group. All P values were two-tailed, and statistical significance was set at P Ͻ .05. The data were analyzed with SPSS 15.0 (SPSS Inc, Chicago, IL).
RESULTS
Patient Characteristics
Patient characteristics are listed in Table 1 . Median age at follow-up was 44 years (range, 23 to 75 years) for all study patients. Median observation time was 11.2 years (range, 5 to 21 years). The age of the RT group was significantly older than that of the surgery group at diagnosis (P Ͻ .001) and at follow-up (P Ͻ .001), whereas the age of the higher-dose group was significantly younger than that of the surgery group at follow-up (P ϭ .002). The higher-dose group also had a shorter observation time than the surgery group (P ϭ .001). The cis/pulmsurg group had a longer observation time compared with the surgery group (P ϭ .04). Compared with the surgery group, the higher-dose group had lower levels of total serum testosterone (␤ ϭ Ϫ2.1; P ϭ .009), higher BMI (␤ ϭ 1.5; P ϭ .006), and fewer pack years of smoking (␤ ϭ Ϫ3.4; P ϭ .047), whereas the cis/pulmsurg group had significantly lower BMI (␤ ϭ Ϫ1.5; P ϭ .04).
Details regarding chemotherapy treatment are listed in Table 2 . Only two patients received more than 360 mg of bleomycin. Although the median bleomycin dose did not differ between the chemotherapy groups (median, 300 mg), the mean bleomycin dose was higher for patients in the higher-dose group than in the lower-dose group (P ϭ .02). The mean etoposide dose was higher (P Ͻ .001), and RPLND was performed more frequently (P ϭ .001), in the higherdose group compared with the lower-dose group. Only two patients in the RT group and three chemotherapy-treated patients received mediastinal irradiation, including one patient in the higher-dose group and one patient in the cis/pulmsurg group.
The majority of patients treated with pulmonary surgery had minor resections (n ϭ 17; 57%). Six patients (20%) had wedge/ segmental resections, three (10%) had lobectomies, three (10%) had thoracotomy with resections of only mediastinal tumors, and one patient (3%) had combined surgery with lobectomy and several resections. No pneumonectomies were performed.
Spirometry Data
Mean unadjusted FVC, FEV1, FVC%pred, and FEV1%pred results according to treatment group are listed in Table 1 . Compared with the surgery group, both the higher-dose group and the cis/pulmsurg group had significantly lower age-adjusted FVC (higher-dose: ␤ ϭ Ϫ.37; P ϭ .001; cis/pulmsurg: ␤ ϭ Ϫ.58; P Ͻ .001; Table 3 ) and FEV1 (higher-dose: ␤ ϭ Ϫ.24; P ϭ .014; cis/pulmsurg: ␤ ϭ Ϫ.55; P Ͻ .001; Table 3 ). Table 4 lists the results of age-adjusted and multiple linear regression analyses, with predicted spirometry values as dependent variables. Compared with the surgery group, all the chemotherapy groups had significantly lower FVC%pred, whereas the higher-dose group and the cis/pulmsurg group had significantly lower FEV1%pred in the age-adjusted analyses. FVC%pred and FEV1%pred were negatively associated with BMI and smoking (pack years) and were positively associated with total testosterone and physical activity in the ageadjusted analyses. In the multiple model, only treatment group (higher-dose and cis/pulmsurg), BMI, and pack years were significantly associated with FVC%pred, whereas treatment group (higherdose and cis/pulmsurg), total testosterone, and pack years were significantly associated with FEV1%pred.
Compared with never-smokers, ever-smokers had lower FVC%pred (␤ ϭϪ2.1; P ϭ .02) and FEV1%pred (␤ ϭ Ϫ3.2; P ϭ .002) results in age-adjusted analyses. Abbreviations: Cis, cisplatin; FVC, forced vital capacity; BMI, body mass index; FEV1, forced expiratory volume in 1 second.
‫ء‬
Dyspnea, Asthma, and Restrictive Lung Disease
Overall, 101 patients (10%) reported having dyspnea, and 27 (2.6%) were classified as having asthma. The higher-dose group had the highest percentage of both dyspnea and prevalent asthma (Fig 1) , but the odds for that group did not differ significantly from those of the surgery group (data not shown).
In total, 84 patients (8.0%) were classified with a restrictive lung disease, and the highest percentages were in the higher-dose group (17.7%) and the cis/pulmsurg group (16.7%; Fig 1) . These two groups also had the highest age-adjusted odds for restrictive lung disease compared with the surgery group (Fig 2) , but a significant difference was noted only for the higher-dose group (odds ratio [OR], 3.1; 95% CI, 1.3 to 7.3). Only eight (9.5%) of the patients classified with restrictive lung disease had self-reported dyspnea, and six (7.5%) had prevalent asthma.
For chemotherapy-treated patients, age older than 40 years at diagnosis was associated with an increased risk for restrictive lung disease (OR, 4.0; 95% CI, 1.2 to 13.4). Major abdominal surgery was not related to risk for restrictive lung disease (OR, 0.83; 95% CI, 0.42 to 1.61).
Impact of Chemotherapy
FVC%pred was negatively associated with cumulative cisplatin (P Ͻ .001), etoposide (P Ͻ .001), and bleomycin (P ϭ .006) doses but not with vinblastine dose (P ϭ .69). In a multiple model that included age and all chemotherapy variables listed in Table 2 , cumulative bleomycin dose (P ϭ .034), cisplatin dose (P Ͻ .001), and age (P Ͻ .001) were significantly associated with FVC%pred.
FEV1%pred was negatively associated with cumulative cisplatin (P Ͻ .001), etoposide (P ϭ .001), and bleomycin (P ϭ .010) doses but not with vinblastine dose (P ϭ .37). In a multiple model, only cisplatin and age (P Ͻ .001 for each) were significantly associated with FEV1%pred.
Cumulative cisplatin dose (P ϭ .007) and etoposide dose (P ϭ .005) were positively associated with the risk for restrictive lung disease, but bleomycin dose (P ϭ .19) and vinblastine dose (P ϭ .90)
were not. In a multiple model, only cisplatin (P ϭ .007) and age (P ϭ .008) were associated with the risk for restrictive lung disease.
Impact of Disease Burden in the Higher-Dose Group
Overall, 22 patients (36%) in the higher-dose group had stage IV (metastatic) disease at initial presentation (Table 1) . Compared with men who were diagnosed with stages I to III disease, these men had received slightly more bleomycin (mean, 299 mg v 263 mg; P ϭ .08) and significantly more cisplatin (mean, 1,302 mg v 1,124 mg; P ϭ .03).
FVC%pred tended to be lower for men who initially had stage IV disease compared with men who had stages I to III disease (88.6% v 94.2%; P ϭ .07). FEV1%pred did not differ between these two groups (89.9% v 91.9%; P ϭ .44), and the risk for restrictive lung disease was similar (18.2% v 17.5%; OR, 1.01; 95% CI, 0.94 to 1.07).
DISCUSSION
To our knowledge, this is the first study to report long-term follow-up spirometry data in a large group of unselected TC survivors. Patients treated with large, cumulative cisplatin doses or with chemotherapy combined with pulmonary surgery had a significantly reduced pulmonary function compared with TC patients treated with surgery only.
The major strength of this study is the large patient population. We have detailed treatment data, which make it possible to study the impact of different treatment modalities and specific chemotherapy agents. Limitations include the cross-sectional study design. Respiratory symptoms, disease status, and medication were self-reported and have not been validated. Another possible limitation is the lack of comparisons to controls from the general population. Limitations with regard to interpretation of our results include the small sample sizes of the higher-dose and the cis/pulmsurg groups.
Prior studies on pulmonary function have focused on lung toxicity as a result of bleomycin. A decrease in the lung transfer capacity for carbon monoxide during chemotherapy treatment is indicative of subclinical bleomycin pulmonary toxicity, 4 ,11 but these reductions in capacity are mostly completely reversible during follow-up. 9, 11, 14 In the majority of previous studies, a decreased vital capacity (VC) and/or FVC was observed during chemotherapy, and normalization was noted at follow-up. 8, [12] [13] [14] There were no spirometry changes during or after chemotherapy treatment in two small, previous clinical studies. 10, 11 Thus, this is the first study to indicate that large cumulative chemotherapy doses are associated with reduced pulmonary function several years after treatment.
Previous studies failed to detect a relationship between cumulative bleomycin doses and spirometry values, 10,11,13 except for one study, in which an association was shown between bleomycin dose and VC.
14 Although we found that bleomycin was significantly associated with FVC%pred, our results indicate a more profound association between the cumulative cisplatin dose and FVC%pred or FEV1%pred. These results are supported by Stuart et al, 16 as they found that VC correlated to number of chemotherapy courses but not to the cumulative bleomycin dose. 16 In fact, the bleomycin dose was not associated with restrictive lung disease in this study. Because the maximum cumulative bleomycin dose was set at 360 mg, the cumulative cisplatin dose, instead, appeared to be the pivotal factor that influences long-term pulmonary function.
Low serum testosterone levels have been associated with a reduction in spirometric variables 30 and an increased risk for respiratory disease mortality in recently published epidemiologic studies.
31,32
Because cisplatin-based chemotherapy may lead to Leydig cell dysfunction, 33 ,34 part of our findings could be related to low serum testosterone. Yet, after the analyses were controlled for testosterone, the cumulative cisplatin dose still had a highly significant impact with respect to the pulmonary function. Cisplatin-based chemotherapy has several long-term organ toxicities, [35] [36] [37] and it is not unlikely that this anticancer agent also affects the lungs. Possible mechanisms include vascular damage and induction of endothelial dysfunction. 38, 39 We found that patients older than 40 years of age at diagnosis had an increased risk for restrictive lung disease. This is in line with a previous large clinical study. 6 As the renal function decreases with age, this increased risk may be due to a reduced renal clearance of chemotherapy agents, such as cisplatin and bleomycin. The small fraction of study participants with a restrictive lung disease pattern who reported having dyspnea may be explained, in part, by coping. We did not ask specifically whether they had exertional dyspnea, which probably would be a better indicator of restrictive lung disease. 40 Because it is well known that thoracic surgery with lung tissue resections influences pulmonary function, 41 we have allocated chemotherapy-treated patients who underwent pulmonary surgery into a separate group. As expected, this group had the largest reductions in the spirometry values. However, because this subgroup included only 30 patients, the number with restrictive disease was merely five patients. Whether abdominal surgery through anesthesia may affect pulmonary function has been more debated, however. Some reports indicate that high oxygen concentrations inspired during surgery in patients who were previously treated with bleomycin may trigger bleomycin-induced pulmonary toxicity, but data are conflicting. [42] [43] [44] [45] [46] Restrictive lung disease did not correlate to major abdominal surgery in our patients, which is in concordance with results presented by O'Sullivan et al. 6 Our findings are of clinical significance for several reasons. First, the effect on the pulmonary function by large cumulative cisplatin doses or by combined chemotherapy and pulmonary surgery equals two-to four-fold the effect of smoking. Second, as much as 17% to 18% of patients in the higher-dose and cis/pulmsurg groups were classified with restrictive lung disease, which is consistent with cisplatin toxicity data presented by Strumberg et al. 7 Third, chemotherapytreated TC survivors have been reported to have an increased respiratory disease mortality with a standardized mortality rate of 2.53. 17 Hence, the chemotherapy treatment appears to result in reduced pulmonary function and is a potential health problem for these survivors.
The reduced pulmonary function among men in the higher-dose group may be caused by factors other than cytotoxic treatment alone. High tumor burden in the lungs and/or recurrent disease may affect the pulmonary status. Our results indicate that men in this subgroup who had stage IV disease tended to have a lower FVC%pred. However, FEV1%pred and the risk for restrictive lung disease did not differ from men who had stages I to III disease.
Nevertheless, intensive treatment with both chemotherapy and surgery is required to maintain and to additionally improve the cure rates for TC patients who have advanced disease. There are, however, several modifiable factors that can be altered to improve the pulmonary status after intensive treatment for TC. These lifestyle factors include smoking cessation, weight control, and regular exercise.
In conclusion, we have identified reduced pulmonary function as a long-term adverse effect after cisplatin-based chemotherapy. Our results are only hypothesis generating, and they need to be confirmed by large prospective studies. This study also underlines the need for long-term follow-up guidelines with regard to pulmonary function. Physicians involved in the treatment and follow-up of these relatively young men should offer essential information about the potential benefits of lifestyle factors and should be aware of early signs of reduced pulmonary function.
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